Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Total Current Liabilities (2016 - 2026)

Iradimed has reported Total Current Liabilities over the past 14 years, most recently at $12.1 million for Q1 2026.

  • Quarterly Total Current Liabilities rose 43.01% to $12.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $12.1 million through Mar 2026, up 43.01% year-over-year, with the annual reading at $10.2 million for FY2025, 19.6% up from the prior year.
  • Total Current Liabilities was $12.1 million for Q1 2026 at Iradimed, up from $10.2 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $16.3 million in Q4 2023 and troughed at $5.6 million in Q3 2022.
  • The 5-year median for Total Current Liabilities is $8.1 million (2024), against an average of $8.8 million.
  • Year-over-year, Total Current Liabilities skyrocketed 90.88% in 2023 and then crashed 47.87% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $8.6 million in 2022, then soared by 90.88% to $16.3 million in 2023, then plummeted by 47.87% to $8.5 million in 2024, then grew by 19.6% to $10.2 million in 2025, then grew by 19.04% to $12.1 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Total Current Liabilities are $12.1 million (Q1 2026), $10.2 million (Q4 2025), and $12.8 million (Q3 2025).